These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36428578)

  • 1. T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer.
    Xue B; von Heyking K; Gassmann H; Poorebrahim M; Thiede M; Schober K; Mautner J; Hauer J; Ruland J; Busch DH; Thiel U; Burdach SEG
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
    Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
    Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.
    Thiel U; Schober SJ; Einspieler I; Kirschner A; Thiede M; Schirmer D; Gall K; Blaeschke F; Schmidt O; Jabar S; Ranft A; Alba Rubío R; Dirksen U; Grunewald TGP; Sorensen PH; Richter GHS; von Lüttichau IT; Busch DH; Burdach SEG
    Oncoimmunology; 2017; 6(5):e1312239. PubMed ID: 28638739
    [No Abstract]   [Full Text] [Related]  

  • 4. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
    Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
    Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.
    Biele E; Schober SJ; Prexler C; Thiede M; Heyking KV; Gassmann H; Eck J; Xue B; Burdach S; Thiel U
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
    Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
    Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
    Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
    Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.
    Schober K; Müller TR; Busch DH
    Cells; 2020 Jun; 9(6):. PubMed ID: 32492858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
    Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
    Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC Class I-Restricted TCR-Transgenic CD4
    Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
    Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
    Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells.
    Kaeuferle T; Stief TA; Canzar S; Kutlu NN; Willier S; Stenger D; Ferrada-Ernst P; Habjan N; Peters AE; Busch DH; Feuchtinger T
    Clin Transl Immunology; 2022; 11(1):e1372. PubMed ID: 35106156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair.
    Moosmann C; Müller TR; Busch DH; Schober K
    STAR Protoc; 2022 Mar; 3(1):101031. PubMed ID: 34977677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.
    Müller TR; Jarosch S; Hammel M; Leube J; Grassmann S; Bernard B; Effenberger M; Andrä I; Chaudhry MZ; Käuferle T; Malo A; Cicin-Sain L; Steinberger P; Feuchtinger T; Protzer U; Schumann K; Neuenhahn M; Schober K; Busch DH
    Cell Rep Med; 2021 Aug; 2(8):100374. PubMed ID: 34467251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
    Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
    BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.
    Miri SM; Tafsiri E; Cho WCS; Ghaemi A
    Cancer Cell Int; 2020; 20():456. PubMed ID: 32973401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
    Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-mediated Gene Knockout Followed by Negative Selection Leads to a Complete TCR Depletion in
    Zhang Q; Yang J; Manoharan ENEA; Yu AB; Milone MC
    Bio Protoc; 2022 Aug; 12(15):. PubMed ID: 36389275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.
    Thiel U; Pirson S; Müller-Spahn C; Conrad H; Busch DH; Bernhard H; Burdach S; Richter GH
    Br J Cancer; 2011 Mar; 104(6):948-56. PubMed ID: 21407224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.